Meanwhile, according to Park et al., the inhibition of the RANK pathway in BRCA1 mutation carriers might be used as a preventive treatment for breast cancer since the researchers observed decreased levels of OPG in BRCA1 carriers [54]. This evidence concerns the gene BRCA1 and breast carcinoma.